Maze Therapeutics (MAZE) Competitors $16.27 +0.26 (+1.62%) As of 01:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. CPRX, ALVO, MIRM, AMRX, OGN, ARWR, IBRX, XENE, NAMS, and GMTXShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Catalyst Pharmaceuticals Alvotech Mirum Pharmaceuticals Amneal Pharmaceuticals Organon & Co. Arrowhead Pharmaceuticals ImmunityBio Xenon Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Maze Therapeutics (NASDAQ:MAZE) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Do analysts recommend MAZE or CPRX? Maze Therapeutics currently has a consensus price target of $23.50, indicating a potential upside of 44.44%. Catalyst Pharmaceuticals has a consensus price target of $32.83, indicating a potential upside of 56.06%. Given Catalyst Pharmaceuticals' higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals and insiders believe in MAZE or CPRX? 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is MAZE or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 36.91% compared to Maze Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 42.45% beat Maze Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A Catalyst Pharmaceuticals 36.91%42.45%36.59% Does the media favor MAZE or CPRX? In the previous week, Maze Therapeutics had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 10 mentions for Maze Therapeutics and 7 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.55 beat Maze Therapeutics' score of 0.79 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger valuation & earnings, MAZE or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M4.25$52.23MN/AN/ACatalyst Pharmaceuticals$534.65M4.80$163.89M$1.5713.40 SummaryCatalyst Pharmaceuticals beats Maze Therapeutics on 11 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$712.63M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.3528.6119.64Price / Sales4.25304.32437.49188.30Price / Cash102.8143.1536.0257.93Price / Book-2.297.718.185.63Net Income$52.23M-$55.11M$3.23B$257.73M7 Day Performance7.89%0.68%-0.25%0.07%1 Month Performance22.24%8.22%5.40%8.32%1 Year PerformanceN/A-2.64%26.35%13.78% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$16.27+1.6%$23.50+44.4%N/A$712.63M$167.50M0.00121CPRXCatalyst Pharmaceuticals4.8952 of 5 stars$21.81-0.2%$32.83+50.5%+25.1%$2.67B$491.73M13.8980Positive NewsALVOAlvotech3.4008 of 5 stars$8.52-2.4%$18.00+111.3%-30.5%$2.63B$491.98M23.031,032Gap UpMIRMMirum Pharmaceuticals3.2933 of 5 stars$52.66-0.7%$65.50+24.4%+31.7%$2.63B$336.89M-32.71140AMRXAmneal Pharmaceuticals2.5657 of 5 stars$8.33-0.7%$11.60+39.3%+12.1%$2.61B$2.83B-208.208,100OGNOrganon & Co.4.8152 of 5 stars$9.94-0.8%$18.00+81.1%-53.9%$2.60B$6.40B3.454,000Trending NewsARWRArrowhead Pharmaceuticals3.5551 of 5 stars$18.31-2.9%$43.71+138.7%-38.9%$2.60B$3.55M-13.08400News CoverageIBRXImmunityBio2.1419 of 5 stars$2.81-2.1%$12.25+335.9%-56.9%$2.53B$14.74M-4.84590XENEXenon Pharmaceuticals3.5727 of 5 stars$32.21-2.3%$54.82+70.2%-24.9%$2.53B$9.43M-9.97210Positive NewsNAMSNewAmsterdam Pharma2.7421 of 5 stars$21.54-2.2%$42.89+99.1%+7.3%$2.47B$45.56M-11.464GMTXGemini TherapeuticsN/A$56.91-1.9%N/A+22.4%$2.47BN/A-56.9130News Coverage Related Companies and Tools Related Companies Catalyst Pharmaceuticals Competitors Alvotech Competitors Mirum Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Organon & Co. Competitors Arrowhead Pharmaceuticals Competitors ImmunityBio Competitors Xenon Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Gemini Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
